Resources Repository
-
BookPublication 2015Methods for the Economic Evaluation of Health Care Programmes, 4th Edition
The 2015 edition of Methods for the Economic Evaluation of Health Care Programmes provides a …
The 2015 edition of Methods for the Economic Evaluation of Health Care Programmes provides a 'tool kit' for undertaking health economic evaluations. The report is aimed at researchers, health service professionals and policy makers without a formal economics background. The recommendations are based on the authors' own experiences and so are practical in nature. The book describes the challenges of allocating resources efficiently and fairly, including challenges in methodology and policy formation. Examples are provided.…
Health Outcomes | Economics/Finance | Preferences/Values | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Value of Information | Mathematical Models | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Science/Technology | Global | North America | Europe -
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Health Outcomes | Economics/Finance | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Global Governance | Health/Medicine | Science/Technology | Global -
ReportPublication 2015Returns on HTA Funded Research
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) …
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) program in making quality research accessible and cost-effective. The authors conduct an economic analysis to illustrate benefits of new interventions in two ways: through improved health, measured in QALYs, and through showing that the intervention allows for the same health outcome and a lower cost. The report utilizes economic analyses and case studies to make recommendations. These recommendations include considering…
Health Outcomes | Economics/Finance | Costing Methods | Evidence Synthesis | Health Systems | Health/Medicine | Science/Technology | Europe -
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Health Outcomes | Economics/Finance | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Health Systems | Policy/Regulation | Clinical Care | Health/Medicine | Asia & Pacific -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Health Outcomes | Economics/Finance | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Social Determinants | Environmental Health | Health Systems | Climate/Environment | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2014Economic Implications of Population Ageing in China & India: Introduction to the Special Issue
In this special issue of The Journal of the Economics of Ageing, we focus on economic …
In this special issue of The Journal of the Economics of Ageing, we focus on economic aspects of population ageing in the world’s two population superpowers: China and India. China and India have been the subject of comparison for many years. Observations about their relative political and economic development abound (see for example Sen, 2013), but little analysis is currently available of their comparative demographic trajectories and the possible economic consequences of the population ageing that they are both undergoing. These demographic…
Health Outcomes | Economics/Finance | Costing Methods | Chronic Disease/Risk | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Asia & Pacific -
BookPublication 2014Decision Making in Health and Medicine: Integrating Evidence and Values
Decision making in health care involves consideration of a complex set of diagnostic, therapeutic and …
Decision making in health care involves consideration of a complex set of diagnostic, therapeutic and prognostic uncertainties. Medical therapies have side effects, surgical interventions may lead to complications, and diagnostic tests can produce misleading results. Furthermore, patient values and service costs must be considered. Decisions in clinical and health policy require careful weighing of risks and benefits and are commonly a trade-off of competing objectives: maximizing quality of life vs maximizing life expectancy vs minimizing…
Health Outcomes | Economics/Finance | Probability/Bayes | Preferences/Values | Costing Methods | Test Performance | Value of Information | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Health Systems | Government/Law | Health/Medicine | Global | North America | Europe | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ReportPublication 2014Redirecting Innovation in U.S. Health Care
This report from RAND Health explores methods of reducing health care spending and developing medical …
This report from RAND Health explores methods of reducing health care spending and developing medical products that provide cost value with health benefits. It summarizes literature and explores case studies to provide policy recommendations to meet these goals. It identifies a wide range of factors that affect the costs, risks, and rewards of medical product invention. Some of these features include treatment creep, the medical arms race, costs and risks of FDA approval, limited reward…
Health Outcomes | Economics/Finance | Costing Methods | Evidence Synthesis | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Science/Technology | North America -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Health Outcomes | Economics/Finance | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Infectious Diseases | Global Governance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific